This episode of the CCI Deep Dive Podcast examines one of the most aggressively marketed—and most misunderstood—areas in regenerative medicine: umbilical cord, amniotic, and placental “stem cell” products. Drawing from published scientific investigations, the discussion breaks down why many of these birth-derived products do not contain functional living stem cells despite bold clinical claims. The episode walks listeners through the hard data, the extremely low viability rates (35–75%)...
All content for Centeno-Schultz Clinic - Podcasts is the property of Centeno-Schultz Clinic Staff and is served directly from their servers
with no modification, redirects, or rehosting. The podcast is not affiliated with or endorsed by Podjoint in any way.
This episode of the CCI Deep Dive Podcast examines one of the most aggressively marketed—and most misunderstood—areas in regenerative medicine: umbilical cord, amniotic, and placental “stem cell” products. Drawing from published scientific investigations, the discussion breaks down why many of these birth-derived products do not contain functional living stem cells despite bold clinical claims. The episode walks listeners through the hard data, the extremely low viability rates (35–75%)...
Dr. Centeno dives into why Chiari malformation symptoms aren’t just about brain structure. This episode reveals how craniocervical instability (CCI) and tiny muscle or nerve issues often drive symptoms—and why surgery isn’t always the answer. Learn how regenerative treatments like the PICL procedure can restore stability and help patients heal without invasive intervention.
Centeno-Schultz Clinic - Podcasts
This episode of the CCI Deep Dive Podcast examines one of the most aggressively marketed—and most misunderstood—areas in regenerative medicine: umbilical cord, amniotic, and placental “stem cell” products. Drawing from published scientific investigations, the discussion breaks down why many of these birth-derived products do not contain functional living stem cells despite bold clinical claims. The episode walks listeners through the hard data, the extremely low viability rates (35–75%)...
